EMA Authorised: Lutathera (lutetium (177Lu) oxodotreotide) — Advanced Accelerator Applications

View source ↗

Summary

European Medicines Agency authorized Lutathera (lutetium (177Lu) oxodotreotide) for neuroendocrine tumors; the product is designated as an orphan medicine and i…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neuroendocrine Tumor

Drugs mentioned

• LUTATHERA (Lutetium Lu-177 dotatate)

Snippet

Status: Authorised. Therapeutic area: Neuroendocrine Tumors. MAH: Advanced Accelerator Applications. Decision date: 03/11/2025. Orphan medicine